Withdrawals due to adverse events · people with Crohn's disease
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
At least 30% reduction in pain · people with Crohn's disease
It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes induction of remission compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes adverse events leading to withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Participants with Crohn's disease in remission
Adalimumab leads to lower failure to maintain clinical remission compared with placebo (high certainty).
2 findings from 1 review
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic response with prior TNF‐α antagonist exposure · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain clinical or endoscopic response with prior TNF‐α… compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain remission · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection)
It is very uncertain whether adalimumab changes failure to maintain endoscopic remission compared with active comparator (very low certainty).
1 finding from 1 review